Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast
May 17, 2018 08:00 ET
|
Immutep Limited
Chief Medical Officer Dr. Frederic Triebel to Present at the 3rd Annual Advances in Immuno-Oncology Congress SYDNEY, Australia, May 17, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM)...
Immutep to Present at 2018 ASCO Annual Meeting
May 04, 2018 04:00 ET
|
Immutep Limited
SYDNEY, Australia, May 04, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (Immutep or the Company) today announced that it will present posters during the 2018 American Society for...
Immutep Completes A$6.31 Million Share Purchase Plan; Raises Total of A$13.16 Million
April 12, 2018 21:24 ET
|
Immutep Limited
SYDNEY, Australia, April 12, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) advises that its Share Purchase Plan (“SPP”) closed as planned on 6 April...
Operational Update
April 02, 2018 20:38 ET
|
Immutep Limited
First two patients of the additional cohort of the Phase I, TACTI-mel trial have commenced treatment; data to be reported mid-2018AIPAC trial: 33 out of a planned 34 clinical sites now active with...
Updated TACTI-mel Data Presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit
March 22, 2018 19:45 ET
|
Immutep Limited
SYDNEY, Australia, March 22, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) is pleased to announce the presentation of updated data from its TACTI-mel...
Immutep Commences Patient Dosing in Additional TACTI-mel Cohort
March 21, 2018 18:29 ET
|
Immutep Limited
SYDNEY, Australia, March 21, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) has announced the initiation of patient dosing in the new cohort of the...
Immutep Raises A$6.85m Through Institutional Placement
March 11, 2018 19:55 ET
|
Immutep Limited
A$6.85m raised through share institutional placement to drive immuno-oncology development programsPlacement of new ordinary shares to leading Australian healthcare institutional investors Platinum...
Immutep Enters Into Clinical Trial Collaboration and Supply Agreement With MSD
March 11, 2018 19:25 ET
|
Immutep Limited
SYDNEY, Australia, March 11, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) has announced that it has entered into a clinical trial collaboration and...
Immutep Announces United States Patent Grant for IMP701 Antibody
March 05, 2018 22:54 ET
|
Immutep Limited
SYDNEY, Australia, March 05, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep”, the “Company”) announces the grant of patent no. 9,908,936 entitled “Antibody molecules to...
Immutep receives A$686,704 R&D Tax Incentive
March 04, 2018 22:27 ET
|
Immutep Limited
SYDNEY, Australia, March 04, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$686,704 cash rebate from...